VIATRIS
Viatris was formed in November 2020 through the combination of Mylan and Pfizer’s Upjohn business, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris’ portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a growing portfolio of biosimilars and a variety of over-the-counter consumer products.
OUR MISSION
At Viatris, we see healthcare not as it is, but as it should be. We act courageously and we are uniquely positioned to be a source of stability in a world of evolving healthcare needs. Our mission is to empower people worldwide to live healthier at every stage of life. We do so via:
Access:
Providing high quality, trusted medicines to patients regardless of geography or circumstance.
Leadership:
Advancing sustainable operations and innovative solutions to improve patient health.
Partnership:
Leveraging our collective expertise to connect people to products and services.
At Viatris, we are pioneering a way to empower companies of any size to leverage our distinctive global healthcare gateway and with collective spirit, driving forward until each challenge is addressed and every opportunity is embraced.
Our shared purpose is to empower people worldwide to live healthier at every stage of life!
CONTACT
General Manager : George Panagakis
Address: 253, Mesogeion Ave. Neo Psychiko, 154 51
- Telephone:+30 210 98 91 777
- Website: https://www.viatris.com